American Rare Earths reports expansion potential at Halleck Creek in Wyoming
Halleck Creek has been named as one of the world’s top 10 rare earth projects.
(via TheNewswire)
Calgary, Alberta – TheNewswire - August 8, 2024 - Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is excited to announce the successful development of a new injector system specifically designed for implantation of the Ocumetics Accommodative Intraocular lens (the “Ocumetics Lens”). This achievement marks a significant milestone in Ocumetics’ journey toward its first-in-human study scheduled for early 2025.
The new injector, meticulously crafted by Medicil, a renowned Swiss IOL (intraocular lens) injector manufacturer, is tailored to the unique specifications of the Ocumetics Lens, ensuring precise and efficient implantation. This development is crucial for optimizing the surgical procedure, performance, and patient outcomes of this innovative lens, which is designed to provide optimal visual performance at all distances and improved quality of life for individuals with visually significant cataracts.
“We are delighted to have completed the development of this specialized injector in collaboration with Medicil,” said Dean Burns, CEO of Ocumetics. “Their expertise and commitment to quality have been instrumental in achieving this milestone. This advancement brings us one step closer to our goal of revolutionizing vision correction after cataract surgery with the Ocumetics Accommodative IOL.”
“We are proud to partner with Medicil on this groundbreaking project,” said Dr Garth Webb, Chief Scientist at Ocumetics. “Our team has worked diligently to develop an injector that meets the high standards that are part of our corporate culture at Ocumetics. We are excited to envision the potential impact this might have on the field of ophthalmology.”
The development of the Ocumetics Lens injector is a pivotal step in preparation for the upcoming first-in-human study. This study, scheduled for early next year, is designed to evaluate the safety and efficacy of the Ocumetics Accommodative IOL in a clinical setting, providing crucial data to support future regulatory applications and commercialization.
For more information about Ocumetics Technology Corp. and our cutting-edge vision enhancement solutions, please visit Ocumetics.com.
About Ocumetics
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.
Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. Ocumetics has developed an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near.
About Medicil
Medicil is a leading Swiss manufacturer of IOL injectors, specializing in the development of high-precision instruments for ophthalmic surgery. With a strong commitment to innovation and quality, Mesicil partners with global companies to deliver cutting-edge solutions that improve surgical outcomes and patient care.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dean Burns Dayton Marks
President and CEO Director
(817) 874-7564 (778) 347-2500
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Copyright (c) 2024 TheNewswire - All rights reserved.
